
The announcement below replaces the RNS issued by
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION
FOR IMMEDIATE RELEASE
("Benchmark" or the "Company")
Result of Tender Offer
Total Voting Rights
and
Directors' Interests
Benchmark, a market leading aquaculture specialist nutrition and health business, is pleased to announce the result of its Tender Offer, details of which were set out in the circular published by the Company on
The maximum aggregate number of Ordinary Shares that could be purchased pursuant to the Tender Offer was 226,934,325 Ordinary Shares at the Tender
Accordingly, a total of 127,720,171 Ordinary Shares will therefore be purchased under the Tender Offer. Of the total number of Ordinary Shares tendered and purchased by the Company, all 127,720,171 Ordinary Shares will be cancelled, with effect from on or around
The total value which will be returned to shareholders of the Company ("Shareholders") pursuant to the Tender Offer will be approximately
·
·
·
With the completion of the Tender Offer, the Company expects to be able to conclude its discussions with Oslo Børs on the final timetable for the cancellation of the trading of its shares from Euronext Oslo. A separate announcement confirming the timetable for the cancellations of admissions to trading on AIM and Euronext Oslo will be released in due course.
Total Voting Rights
Following the closing of the Tender Offer and the cancellation of 127,720,171 Ordinary Shares referred to above, the Company will have 614,702,942 Ordinary Shares in issue. Therefore, the total number of voting rights in the Company will be 614,702,942 which may be used by Shareholders as the denominator in the calculations by which they may determine if they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.
Directors' Interests
As set out in the Circular, the Company received irrevocable undertakings from each member of the
|
Number of Ordinary Shares held pre and post Cancellation |
% of the Company's total voting rights immediately following Cancellation |
|
191,923,746 |
25.85 |
|
162,618,130 |
21.90 |
|
6,645,681 |
0.90 |
|
165,215,579 |
22.25 |
TOTAL |
526,403,136 |
70.90 |
Notes:
(1) All of FERD AS's and Kverva Finans AS's holdings are held through the structure implemented for the trading of the Ordinary Shares on Euronext Oslo Growth and are therefore registered in the name of Euroclear Nominees Limited as custodian for DNB and held by DNB as nominee in The Norwegian Central Securities Depository (Euronext Securities Oslo).
(2) JNE Partners LLP is the investment manager of each of JNE Master Fund LP and JNE Illiquid Opportunities Fund LP and the Ordinary Shares are registered in the names of Goldman Sachs Securities (Nominees) Ltd. and Citibank, N.A respectively and held by Goldman Sachs Securities (Nominees) Ltd. and Citibank, N.A respectively as nominee.
Capitalised terms used in this announcement (unless otherwise defined) have the meanings set out in the Circular.
The information communicated in this announcement contains inside information for the purposes of Article 7 of the
The person responsible for arranging the release of this announcement on behalf of the Company is
Enquiries
|
|
|
|
Strand
|
+44 (0) 20 727409 3494
+44 7831 406117
|
ABOUT BENCHMARK
Benchmark is a market leading aquaculture biotechnology company. Benchmark's mission is to drive sustainability in aquaculture by delivering products and solutions in advanced nutrition and health which improve yield, growth and animal health and welfare. Find out more at www.benchmarkplc.com
PUBLICATION ON A WEBSITE
A copy of this announcement will be made available at https://www.benchmarkplc.com/ no later than 12:00 noon (
OTHER NOTICES
This announcement is not intended to and does not constitute an offer to buy or the solicitation of an offer to subscribe for or sell or an invitation to purchase or subscribe for any securities or the solicitation of any vote in any jurisdiction. The release, publication or distribution of this announcement in whole or in part, directly or indirectly, in, into or from certain jurisdictions may be restricted by law and therefore persons in such jurisdictions should inform themselves about and observe such restrictions.
Strand
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the